IMCR Q4 2025 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M-7.9% YoY

Gross Profit

$75M96.6% margin

Operating Income

-$15M-18.8% margin

Net Income

-$22M-28.8% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-25.3%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$36M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$686M

Stockholders' Equity

$381M

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$84M	-7.9%
Gross Profit	$75M	$84M	-10.6%
Operating Income	-$15M	-$19M	+25.0%
Net Income	-$22M	-$24M	+6.3%

Revenue Segments

Sale of Therapies

$104M100%

Geographic Segments

UNITED STATES

$69M66%

Europe

$32M31%

Rest of World

$3M3%